Company intelligence / Profile preview

Glycanostics

Ownership: Private
Development stage: Preclinical

Overview

Glycanostics has developed a patented diagnostic platform that analyzes changes in glycans attached to serum proteins to enable highly accurate and non-invasive early detection of multiple cancers. Their flagship GIASAY Prostate test aims to reduce unnecessary biopsies by improving specificity over current PSA testing. The company’s breast, pancreatic and lung cancer tests are advancing through clinical validation with support from major EU grants. CE certification for the first products is expected soon.

Therapeutic areas: Oncology
Modalities: Diagnostic tests (liquid biopsy based on glycan analysis)
Industry: Protein Biomarker Diagnostics

Beyond the preview

Go deeper on Glycanostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Glycanostics.

Explore the full profile